『Compounding Interest』のカバーアート

Compounding Interest

Compounding Interest

著者： Amy Summers
無料で聴く

Welcome to Compounding Interest: The Business of Personalized Medicine, the podcast exploring what it takes to build, scale, and safeguard high-performing operations in the rapidly evolving world of personalized medicine. Hosted by Amy Summers, PharmD, BCSCP, FAPC - a nationally recognized authority in pharmacy compounding and 503B outsourcing operations - and backed by the expert team at Restore Health Consulting, this show features insightful conversations with healthcare innovators, compliance executives, and life science operators who are rethinking what it means to deliver specialized care in a highly scrutinized landscape. Each episode examines the rigorous regulatory frameworks, quality systems design, and strategic leadership approaches that help organizations elevate their operations far beyond basic compliance. Through real-world insights and field-tested strategies, guests share how they navigate complex guidelines, optimize 503A and 503B facilities, and transform strict quality controls into an organizational strength. Drawing from a deep portfolio of enterprise-level operational transformations and proven industry playbooks, the show explores how an unwavering dedication to clinical and operational excellence can become a powerful differentiator when organizations intentionally design businesses built to scale.Copyright 2026 Amy Summers 衛生・健康的な生活 身体的病い・疾患
エピソード
  • New Episode Coming Soon!

    New Episode Coming Soon!
    2026/06/26

    Are you overwhelmed by complex compliance codes and shifting regulatory standards? Do you worry that your quality management systems are just checking boxes instead of truly safeguarding your operations?

    You don't have to navigate the high-stakes landscape of sterile compounding and personalized medicine alone.

    Introducing Compounding Interest: The Business of Personalized Medicine! Brought to you by Amy Summers - a nationally recognized authority in 503A and 503B operations - and the expert team at Restore Health Consulting. Backed by proven playbooks and a nationwide consulting network, they help businesses build, scale, and restore their infrastructure to maximum capacity.

    In each episode, you will gain executive-level insights, field-tested risk mitigation strategies , and inspection-ready solutions that help organizations move past minimum standards and achieve true operational excellence. If you are a pharmacy operator, life sciences executive, or medical spa innovator, this is your essential guide.

    Compounding Interest is coming soon to your favorite podcast platform. Subscribe now so you don't miss the very first episode!
    続きを読む 一部表示
    1 分
  • The Peptide Therapy Crisis for Patients Losing Access to Life-Changing Treatments with Melissa Stefko

    The Peptide Therapy Crisis for Patients Losing Access to Life-Changing Treatments with Melissa Stefko
    2026/07/03
    The future of peptide compounding is at a critical crossroads. As the FDA prepares for its upcoming Pharmacy Compounding Advisory Committee (PCAC) meeting, compounders, prescribers, patients, and industry advocates are facing important decisions that could shape access to peptide therapies for years to come. In this episode, Amy Summers sits down with Melissa Stefko of Wells Pharmacy Network to discuss why these regulatory decisions matter. Together they explore the intersection of personalized medicine, patient access, regulatory oversight, and public safety.Melissa Stefko is the senior VP of regulatory affairs at Wells Pharmacy Network with extensive experience in pharmacy compounding and FDA policy. She has been actively involved in peptide nominations for FDA review and works closely with industry organizations advocating for safe, regulated access to compounded therapies. Melissa brings a practical perspective on how evolving regulations impact pharmacies, physicians, and patients seeking personalized medicine.Key TakeawaysWhy the upcoming FDA PCAC meeting could significantly impact peptide compounding.How peptide therapy fits into the growing movement toward personalized medicine.The safety concerns surrounding the expanding gray market for peptides.The difference between FDA enforcement discretion and state board pharmacy regulations.How pharmacists, physicians, and patients can contribute meaningful comments before FDA review.Timestamps[00:00] - Introduction to the episode[04:07] - Why peptides have become a major healthcare and regulatory topic[08:08] - Clinical uses for peptides and the original FDA nominations[11:05] - FDA's preliminary recommendations and industry concerns[15:16] - Gray market peptides versus regulated pharmacy compounding[18:35] - Understanding FDA oversight and state board enforcement[22:24] - How pharmacies, physicians, and patients can support the FDA review process[26:08] - What meaningful FDA docket comments should include[28:19] - Possible outcomes after the PCAC meeting[33:10] - Final recommendations and how stakeholders can get involvedFollow Melissa Stefko:LinkedIn: https://www.linkedin.com/in/melissa-stefko-70234415/Website (Company): https://wellsrx.com/LinkedIn (Company): https://www.linkedin.com/company/wellspharmacynetwork/Facebook (Company): https://www.facebook.com/wellsrxInstagram (Company): https://www.instagram.com/wellspharmacynetwork/X (Company): https://x.com/wellsrxTikTok (Company): https://www.tiktok.com/@wellspharmacynetworkFollow the Host:Amy Summers: https://www.linkedin.com/in/amy-summers-pharmd-bcscp-fapc-20b04a93/Restore Health Consulting: https://www.restorehealthconsulting.com/Follow The Podcast:YouTube: https://www.youtube.com/@RestoreHealthConsultingSpotify: https://open.spotify.com/show/033F4FRUbjSrN1oNbfozhD?si=caf30ccfd2ba49b6Apple Podcasts: https://podcasts.apple.com/in/podcast/compounding-interest/id6784679391
    続きを読む 一部表示
    34 分
  • What Compounding Pharmacies Cannot Say About Safety & Effectiveness in Medicine – Darshan Kulkarni

    What Compounding Pharmacies Cannot Say About Safety & Effectiveness in Medicine – Darshan Kulkarni
    2026/07/21
    The personalized medicine and compounding pharmacy industry is evolving rapidly as patient demand, regulatory scrutiny, and technological innovation continue to collide. In this episode of Compounding Interest: The Business of Personalized Medicine, host Amy Summers sits down with Darshan Kulkarni to explore the legal and ethical challenges facing compounding pharmacies today. From FDA advertising rules and promotional claims to USP 797, 503A vs. 503B pharmacies, peptides, and the future of personalized medicine, this conversation examines where innovation meets regulation and where the industry's biggest gray areas remain.Darshan Kulkarni, PharmD, MS, Esq., is a pharmacist, attorney, educator, author, and founder of Kulkarni Law Firm, where he advises FDA-regulated industries on complex regulatory and compliance matters for the Life Sciences. His expertise spans pharmacy compounding, medical devices, advertising compliance, clinical research, and FDA law. His multidisciplinary background provides a unique perspective on balancing patient access, innovation, and regulatory responsibility.Key TakeawaysWhy patient safety, efficacy, affordability, and access must all be balanced in personalized medicine.The legal boundaries surrounding advertising and promotional claims for compounding pharmacies.How FDA regulations, USP 797, and 503A/503B distinctions impact pharmacy operations.The regulatory challenges surrounding peptides, compounded medications, and personalized therapies.Practical guidance for pharmacies navigating compliance while continuing to serve patients effectively.Timestamps[00:00:00] - Introduction to Darshan Kulkarni and Personalized Medicine: Amy introduces Darshan and discusses how his pharmacy and legal background shapes his perspective.[00:05:15] - The Purpose and Evolution of Pharmacy Compounding: A discussion on FDA oversight, drug shortages, the NECC tragedy, and the growth of modern compounding.[00:09:53] - Common Compliance Mistakes in FDA-Regulated Industries: Darshan explains the regulatory issues he sees most often across healthcare companies.[00:14:09] - Marketing Rules for Compounding Pharmacies: Which advertising claims pharmacies should avoid and how they can market responsibly.[00:21:59] - Why Disclaimers Cannot Replace Regulatory Compliance: Understanding the limits of disclaimers in pharmaceutical advertising.[00:26:01] - Peptides and the Ongoing Regulatory Debate: A discussion on safety, efficacy, patient access, and the legal concerns surrounding peptide products.[00:31:13] - Buying a Compounding Pharmacy: Darshan shares advice on finding acquisition opportunities through networking, brokers, and industry relationships.[00:32:55] - Closing Thoughts and Final Takeaways: Amy wraps up the conversation by reflecting on the importance of thoughtful debate in personalized medicine.Follow Darshan Kulkarni:LinkedIn: https://www.linkedin.com/in/darshankulkarni/Website (Company): https://kulkarnilawfirm.com/LinkedIn (Company): https://www.linkedin.com/company/kulkarnilaw/ X (Company): https://x.com/kulkarnilawfirmYouTube: www.youtube.com/@DarshanTalksFollow the Host:Amy Summers: https://www.linkedin.com/in/amy-summers-pharmd-bcscp-fapc-20b04a93/Restore Health Consulting: https://www.restorehealthconsulting.com/Follow The Podcast:YouTube: https://www.youtube.com/@RestoreHealthConsultingSpotify: https://open.spotify.com/show/033F4FRUbjSrN1oNbfozhD?si=caf30ccfd2ba49b6Apple Podcasts: https://podcasts.apple.com/in/podcast/compounding-interest/id6784679391
    続きを読む 一部表示
    33 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません